ClinicalTrials.gg
Not yet recruitingNCT07143032Updated Aug 27, 2025

A Comparative Study Between Three Surgical Techniques in Large Angle Exotropia

An interventional study of Extropia squint surgery in Exotropia Equal or More Than 50 Prism Diopter, sponsored by Sohag University. Not yet recruiting. Open to participants aged 3 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Sohag University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
3 Years to 50 Years
Sex
All
01

Study summary

This is a randomized comparative interventional study that aims to compare the surgical outcomes of correcting large angle exotropia (≥50 prism diopter) by three different surgical techniques including: 1/ bilateral lateral rectus muscle recession with unilateral medial rectus muscle resection 2/bilateral medial rectus muscle resection, 3/unilateral medial rectus muscle resection with lateral rectus muscle transplantation,

Read the detailed description

This is a randomized comparative interventional study that will be conducted on patients with large angle exotropia before and after doing surgical correction using three different surgical techniques including : 1/ bilateral lateral rectus muscle recession with unilateral medial rectus muscle resection 2/bilateral medial rectus muscle resection, 3/unilateral medial rectus muscle resection with lateral rectus muscle transplantation ,to compare the surgical outcomes between them.

02

Conditions studied

  • Exotropia Equal or More Than 50 Prism Diopter

Browse trials for

Keywords

  • exotropia
  • Recession
  • Resection
  • Transplantation
03

In context

Exotropia

58 studies on the registry are indexed under Exotropia; 13 are open to participants now.

This study's planned enrollment of 60 is above the median of 50 across 49 interventional studies indexed under Exotropia.

Browse Exotropia studies →

Lead sponsor

Sohag University is the lead sponsor of 1,230 studies on the registry; 636 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with large-angle exotropia (≥50 prism diopter).

Exclusion criteria

Exclusion Criteria:

  1. Patients with an exodeviation angle of less than 50 prism diopter.
  2. History of previous strabismus surgery.
  3. Restrictive or paretic strabismus or history of botulinum toxin injections for strabismus.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    bilateral lateral rectus muscle recession with unilateral medial rectus muscle resection

    patients with large angle exotropia treated by bilateral lateral rectus muscle recession with unilateral medial rectus muscle resection

    Procedure: Extropia squint surgery

  • Active comparator
    bilateral medial rectus muscle resection

    patients with large angle exotropia treated by bilateral medial rectus muscle resection

    Procedure: Extropia squint surgery

  • Active comparator
    unilateral medial rectus muscle resection with lateral rectus muscle transplantation

    patients with large angle exotropia treated by unilateral medial rectus muscle resection with lateral rectus muscle transplantation

    Procedure: Extropia squint surgery

Interventions

  • ProcedureExtropia squint surgery

    patients with large angle exotropia will be treated by three different surgical techniques including: 1/ bilateral lateral rectus muscle recession with unilateral medial rectus muscle resection 2/bilateral medial rectus muscle resection, 3/unilateral medial rectus muscle resection with lateral rectus muscle transplantation ,to compare the surgical outcomes between them.

06

What researchers measure

Primary outcomes

  1. changes in ocular alignment

    Detect ocular alignment by using Krimsky test to measure angle of deviation in prism diopter

    Time frame: at one month, 6 month and one year postoperatively.

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Cifuentes DL, Pineles SL, Demer JL, Velez FG. Surgical success and lateral incomitance following three-muscle surgery for large-angle horizontal strabismus. J AAPOS. 2018 Feb;22(1):17-21. doi: 10.1016/j.jaapos.2017.10.005. Epub 2017 Dec 1. PubMed 29199031 ↗
  • Talebnejad MR, Johari MK, Khalili MR, Zare M. Supramaximal Recession and Resection Surgery in Large-Angle Strabismus: Outcomes of Large Interventional Case Series Exotropia and Esotropia. J Curr Ophthalmol. 2020 Mar 23;32(1):82-87. doi: 10.4103/JOCO.JOCO_22_20. eCollection 2020 Jan-Mar. PubMed 32510018 ↗
  • Peters ER, Archer SM. Long-standing, large-angle exotropia in adults. Am Orthopt J. 2007;57:104-6. doi: 10.3368/aoj.57.1.104. PubMed 21149163 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jul 2027, 22 months later.

Of 29 interventional studies with no phase under Exotropia, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 46. This study's planned 22 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 27, 2025
StartEst.
Sep 2025
Primary completionEst.
Jul 2027
CompletionEst.
Sep 2027
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07143032
Lead sponsor
Sohag University
Responsible party
Sara Ahmed Abdelraheem (Principle investigator, Sohag University) — Principal investigator
First posted
Aug 27, 2025
Start date
Sep 2025 (estimated)
Primary completion
Jul 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Aug 27, 2025

Study contacts

sara ahmed abdelraheem, Assistant lecturer
Contact
sara011096@med.sohag.edu.eg
+201153987387
Alahmady Hamad Alsaman, Professor
Contact
+201111102698

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion